Shenderey K, Marsh B T, Talbot D J
Pharmatherapeutica. 1985;4(5):300-5.
Seven-day courses of either 200 mg pivmecillinam plus 250 mg pivampicillin given twice daily or 250 mg amoxycillin given 3-times daily were compared in a multi-centre general practice study in 350 patients with symptoms of upper or lower respiratory tract infection. Patients were stratified into four diagnostic groups: sinusitis, otitis media, throat infections, and acute bronchitis, and randomly allocated to treatment within these groups. Assessments at 7 days showed no difference in overall clinical efficacy between the two treatments; however, patients with acute bronchitis showed a better response to pivmecillinam plus pivampicillin. After treatment, signs of infection were absent in 139 (79%) patients in the pivmecillinam plus pivampicillin group and in 143 (80%) patients in the amoxycillin group. Both treatments were well tolerated, adverse effects being reported in only 17 (9.8%) patients after pivmecillinam plus pivampicillin and 15 (8.6%) patients after amoxycillin. These were mainly associated with disturbances of the gastro-intestinal tract where reports of diarrhoea were twice as common after amoxycillin.
在一项针对350例有上呼吸道或下呼吸道感染症状患者的多中心全科医疗研究中,比较了两种治疗方案:一是每日两次给予200毫克匹美西林加250毫克匹氨西林,疗程7天;二是每日三次给予250毫克阿莫西林,疗程7天。患者被分为四个诊断组:鼻窦炎、中耳炎、咽喉感染和急性支气管炎,并在这些组内随机分配接受治疗。7天时的评估显示,两种治疗方案的总体临床疗效无差异;然而,急性支气管炎患者对匹美西林加匹氨西林的反应更好。治疗后,匹美西林加匹氨西林组139例(79%)患者和阿莫西林组143例(80%)患者的感染体征消失。两种治疗方案的耐受性均良好,匹美西林加匹氨西林治疗后仅有17例(9.8%)患者报告有不良反应,阿莫西林治疗后有15例(8.6%)患者报告有不良反应。这些不良反应主要与胃肠道不适有关,其中阿莫西林治疗后腹泻报告的发生率是匹美西林加匹氨西林治疗后的两倍。